Loengard Anna U's Form 4 filing
Clover Health Investments, Corp. (CLOV) · filed Mar 18, 2024
- Accession no.
- 0001801170-24-000068
- Filed
- Mar 18, 2024
- Trade date
- Mar 14, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $110.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Loengard Anna UCIK 0001952723 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2024 | Class A Common Stock | PPurchaseAcquired | +137,000 | $0.73F1 | +$100,010 | 538,841 | Direct | |
| Mar 14, 2024 | Class A Common Stock | PPurchaseAcquired | +13,625 | $0.73 | +$9,946.25 | 15,125 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average purchase price. These shares were purchased on the Transfer Date in multiple transactions at prices ranging from $0.73 to $0.74 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.